pharmaceuticals news from FierceBiotech
NewsEnzon spins off biotech ops into $150M enterprise
Enzon Pharmaceuticals has decided to spin off its biotech operations into a new company, adopting a suggestion floated by none other than Carl Icahn. Icahn has Read more...
SPOTLIGHT: Mystery Mistral merger is off
Canada's Mistral Pharma says its proposed merger with an unnamed U.S. specialty pharma company will not be completed. As a result, its bridge financing deal has been canceled and management has Read more...
Report: GSK to fund venture firm, back start-ups
In Vivo is reporting that GlaxoSmithKline plans to set aside up to $500 million for a new venture fund that will support its internal R&D work as well as fund start-ups created from Read more...
Esperion gets second shot as an independent drugmaker
After getting squashed in Pfizer's restructuring crunch, Esperion Therapeutics is reopening this week. The company, which specializes in cardiovascular and metabolic disease work, is hiring about 10 Read more...
Roche expands Memory pact
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...
Pfizer spins off Esperion as VCs ante up $22.75M
Pfizer has spun of Esperion Therapeutics into a new biotech company aiming to develop new therapies for cardiovascular and metabolic disease. A syndicate of investors funded the deal. Pfizer sold Read more...
Concert tech strikes chord with $37M VC round
Even before its first compound hits the clinic, Concert Pharmaceuticals is having no trouble raising venture funds. The Lexington, MA-based developer has just ginned $37 million in a new venture Read more...
Booming Chinese market lures Unigene joint venture
Unigene is racing to complete construction of new facilities in China that will house its joint venture with a Chinese pharma company. The joint venture plans to pursue R&D work as well as drug Read more...
Baltimore plays a losing economic development hand
Economic development officials in Baltimore are fretting that they're one step behind the pace being set in Montgomery County, where low-cost lab space along with offers of small loans and grants Read more...
UCB CEO plots strategy following Cimzia approval
Fresh off the FDA's approval of Cimzia for Crohn's disease, UCB chief executive Roch Doliveux forecast a swift regulatory success in Europe. Cimzia is one of the most closely watched late-stage Read more...
| Whitepapers and ReportsPharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan Pharmaceutical Pricing and Reimbursement examines the tactical importance of price optimization throughout the product lifecycle. The key issues affecting pricing and reimbursement disciplines are Read more... |
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight